No difference in malignancy rates seen between tocilizumab and TNFi in patients with RA
(European League Against Rheumatism) The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) examined rates of malignancy in patients with rheumatoid arthritis (RA), excluding non-melanoma skin cancer (NMSC), and found no difference between those newly treated with tocilizumab (TCZ) versus TNF inhibitors (TNFi).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Actemra | Arthritis | Cancer | Cancer & Oncology | Melanoma | Nonmelanoma Skin Cancer | Politics | Rheumatoid Arthritis | Rheumatology | Skin | Skin Cancer | Study